WATERTOWN, MA, JUNE 1, 2016 – JWRG’s multi-year effort to broaden the content of disease-specific health-related quality of life (QOL) measures and to standardize their scoring in relation to norms for the chronically ill US population has been documented in an article about the Quality of life Disease Impact Scale (QDIS®), published in Health and Quality of Life Outcomes. QDIS is a suite of disease-specific measures, including a 49-item bank which can be used in computerized adaptive testing, a 7-item fixed-length short form and a global QOL item, each of which estimates a summary QOL disease impact score. The content of QDIS questions is standardized across conditions, but questions vary in their disease-specific attribution. For example, a QDIS question for chronic kidney disease might ask “How much did your kidney disease limit your everyday activities or your quality of life?”, while the same question also might be asked with attribution to asthma or diabetes. Impact scores for these and ...Read More
WORCESTER, MA, January 8, 2016 -- Researchers at UMass Medical School and JWRG have published results that open up a new pathway to disease-specific quality of life (QOL) impact measurement, as reported in a special issue of International Journal of Statistics in Medical Research (IJSMR) on methods for estimating treatment effects for persons with multiple chronic conditions (MCC). This study, sponsored by the Agency for Healthcare Research and Quality (AHRQ), evaluated alternative approaches to measuring disease-specific impact across people who reported MCC. Results demonstrated the feasibility of JWRG’s new approach to individualized disease impact measurement
The QOL Disease-specific Impact Scale (QDIS®), which standardizes content and scoring across diseases, is central to ...Read More
WORCESTER, MA, August 10, 2015 – Results from an article published in Health and Quality of Life Outcomes link a new smoking-specific quality of life measure based on JWRG’s QOL Disease Impact Scale (QDIS®) to smoking behavior and to smoking-specific symptoms. This article presented data from two independent studies: a German trial and a US general population survey. Like many others, these studies both focused on young and otherwise healthy current and former adult smokers. Both studies found that the QDIS smoking impact scale had stronger associations than the generic SF-36® Health Survey with smoking status (current versus former) and the number of cigarettes smoked per day. In the German trial, which also included laboratory test results, the QDIS smoking impact measure also correlated substantially and significantly higher than the SF-36 with four clinical biomarkers of tobacco exposure and impact. These and other results showed that the German- and English-language QDIS smoking impact scale and other meas ...Read More
WORCESTER, MA, April 27, 2015 – A new quality of life instrument, the Tobacco Quality of Life Impact Tool (TQOLIT™), developed by the John Ware Research Group, was proven to be useful in a 6-month clinical trial of the effects of switching smokers to a reduced toxicant prototype cigarette. Like many smoking studies, this trial focused on young and otherwise healthy adult current and former smokers for whom reliable measurement throughout the range of functional health and well-being is critical. The results were recently published in Nicotine & Tobacco Research.
Measuring the health-related quality of life (HRQOL) of young and middle-aged smokers is challenging because many of the impacts of smoking are not apparent for decades. In addition, prior to QDIS there was no brief HRQOL scale that measured the impact of smoking on physical, emotional and social aspects of life. TQOLIT integrates several JWRG advances in patient-reported outcomes (PRO) measurement to address these challenges.
First, TQOLIT includes a short 7-item scale that measur ...Read More
WORCESTER, MA, February 10, 2015 – A national registry recently conducted a field test to collect patient-reported outcomes (PRO) data using a new method. Patients logged on from home or the clinic to complete the survey, as is typical for web-based assessments, before and after total joint replacement (TJR). The difference was in what happened next. The survey used the Quality of Life (QOL) Information System (QOLIX®) which uses a powerful new adaptive survey logic (ASLX®) to automatically adapt to the presence of multiple comorbid conditions while also estimating outcomes with metrics equivalent to those underlying widely-used legacy PROs. Although each of the major elements of QOLIX, including standardized disease-specific (QDIS®) and generic (QGEN®) modules, and the power of ASLX had been evaluated successfully in real data simulations, this was the first real-world test of the entire system in an ongoing PRO registry. Des ...Read More
WORCESTER, MA, January 29, 2015 -- JWRG’s pursuit of disease-specific QOL measurement innovation appears to be on the right track toward filling the gap between disease-specific measures that do not measure QOL and QOL measures that are not disease-specific.
Studies conducted during the development of the Quality of Life Disease Impact Scale (QDIS®) showed that it differs from widely-used disease-specific measures in a number of important ways. First, QDIS increases disease-specific QOL content representation enough to be on a par with widely-used generic QOL measures. At the same time, QDIS provides a single overall QOL impact score, despite its breadth of content. While QDIS item content overlaps substantially with the item content of generic measures, because QDIS items are disease-specific, QDIS consistently achieves greater convergent and discriminant validity in comparison with generic measures. QDIS also is the first disease-specific measure to be scored using norm-based scoring, based on a representative sample of the entire U.S. chronically ill general population, a ...Read More
WORCESTER, MA, May 30, 2014. The Agency for Health Research and Quality (AHRQ) announced the award of a grant to Dr. John Ware and researchers he leads at UMass Medical School and JWRG to break new ground by taking a previous measurement advance into a new direction. An innovative computerized measurement advance, the Quality of Life Disease Impact Scale (QDIS®), makes it much easier to gather individualized information from patients who have multiple chronic conditions. QDIS was developed by JWRG to rapidly and reliably determine how much each individual chronic condition a patient has and all comorbid conditions combined affect what they are able to do, how they feel and their overall quality of life (QOL). The ultimate goal is to better quantify patient “voices” to better understand how to improve the outcomes of their care. The R&D project uses a large national database already collected by JWRG for representative samples of chronically-ill US adults. The information it contains is unique because it is the first to standardize both the content and scoring of dise ...Read More
WORCESTER, MA, March 17, 2014 – Some of the most debated questions regarding growing reliance on patient-reported outcome (PRO) surveys in evaluating the quality of health care were addressed in an article by a medical student and a professor today in Medical Care, a research journal published by the American Public Health Association.
According to the most comprehensive review of quality of life outcomes reported from well-controlled clinical trials of drug therapies, the answer to the first question is “Yes,” more than 80% of the time. However, there is wide variability in the rates at which drug treatments achieved accepted thresholds for improvements in quality of life (about 58% overall; 0-100% across clinical areas). For exampl ...Read More
WORCESTER, MA, January 15, 2013 -- Dr. John E. Ware, Jr., Chief Science Officer and Founder of John Ware Research Group, Inc. (JWRG), a leading health outcomes company, was elected a Charter Fellow of the National Academy of Inventors (NAI). The NAI recognizes inventors who hold U.S. patents. Nominated by the University of Massachusetts Medical School where Dr. Ware is also Professor and Chief of the Outcomes Measurement Sciences Division in the Department of Quantitative Health Sciences, Dr. Ware said, "it is an honor to be an NAI Charter Fellow and to be in the company of such distinguished innovators." Dr. Ware, holder of numerous awards, is a globally recognized inventor in the patient reported outcomes (PRO) field. PROs are used in clinical trials and healthcare, including medical practice and electronic health records. PROs measure treatment outcomes, now at the forefront of healthcare reform. The newly elected NAI class of Fellows is comprised of inventors and innovators from 56 global research universities and non-profit researc ...Read More
John Ware Research Group (JWRG) is a privately held company founded in 2009 by John E. Ware, Jr., PhD to continue innovative research to improve patient-reported outcome (PRO) tools for use in population health surveys, clinical research and clinical practice worldwide.
Phone: +1 (508) 363-1236
10 Wheeler Court, Watertown, MA 02472